Response Genetics (RGDXQ) Stock Price, News & Analysis

Company Overview

Response Genetics, Inc. is a molecular diagnostics company specializing in precision oncology. The firm applies genomic profiling and biomarker analysis to help guide treatment decisions for cancer patients. By leveraging proprietary technologies and a CLIA-certified, CAP-accredited laboratory infrastructure, Response Genetics delivers comprehensive insights into tumor biology to support personalized medicine.

The company’s core offerings include predictive biomarker assays such as its legacy TheraGuide™ companion diagnostic tests, which assess key mutations linked to targeted therapies, and its OncoSelect™ next-generation sequencing panels, designed to detect a broad spectrum of genomic alterations. These assays focus on indications such as non-small cell lung cancer, colorectal cancer and melanoma, providing information on common drivers like EGFR, KRAS, ALK and BRAF to inform treatment selection.

In addition to its testing services, Response Genetics partners with pharmaceutical companies and clinical research organizations to co-develop and validate companion diagnostics that complement drug development programs. The company’s high-throughput capabilities and robust data management systems enable efficient sample processing, analytical rigor and regulatory support for clinical trials.

Founded in the early 2000s and headquartered in Los Angeles, California, Response Genetics serves oncology clinics and research centers across the United States. Over its history, the company has aimed to accelerate the translation of biomarker discovery into practical diagnostic tools, helping clinicians tailor therapies and improve outcomes for cancer patients.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RGDXQ Stock Analysis - Frequently Asked Questions

How do I buy shares of Response Genetics?

Shares of RGDXQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 9/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:RGDXQ
• Previous Symbol: NASDAQ:RGDX
• CIK: 1124608
• Web: www.responsegenetics.com
• Phone: (323) 224-3900
• Fax: 323-224-3096
• Employees: 100
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A